LivaNova PLC (NASDAQ:LIVN) Shares Purchased by Squarepoint Ops LLC

Squarepoint Ops LLC increased its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 74.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 111,449 shares of the company's stock after purchasing an additional 47,494 shares during the quarter. Squarepoint Ops LLC owned 0.21% of LivaNova worth $5,161,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of LivaNova by 12.7% during the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock worth $108,823,000 after purchasing an additional 265,291 shares during the last quarter. Capital Research Global Investors increased its stake in LivaNova by 19.1% during the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock worth $74,690,000 after buying an additional 258,730 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in LivaNova by 8.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company's stock worth $60,710,000 after buying an additional 107,693 shares in the last quarter. Redmile Group LLC increased its stake in LivaNova by 19.3% during the 4th quarter. Redmile Group LLC now owns 1,043,539 shares of the company's stock worth $48,326,000 after buying an additional 168,500 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its stake in LivaNova by 0.6% during the 4th quarter. Nuveen Asset Management LLC now owns 823,412 shares of the company's stock worth $38,132,000 after buying an additional 5,080 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Stock Performance

LIVN traded down $1.23 on Wednesday, hitting $42.79. 513,422 shares of the company traded hands, compared to its average volume of 651,185. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $61.94. The company has a 50 day moving average of $38.86 and a 200-day moving average of $44.48. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $2.33 billion, a PE ratio of 101.88 and a beta of 0.84.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Robert W. Baird lifted their price objective on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Barclays lowered their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research report on Thursday, May 8th. Needham & Company LLC restated a "buy" rating and set a $64.00 price target on shares of LivaNova in a research report on Tuesday, May 13th. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target for the company in a research report on Tuesday, May 20th. Finally, Stifel Nicolaus lowered their price target on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $59.29.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.